Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4755-4759

  Aldulaymi, Bahir ^a   Christensen, Ib J ^b   Sölétormos, György ^a   Jess, Per ^a   Nielsen, Svend Erik ^a   Laurberg, Søren ^c   Brünner, Nils ^d   Nielsen, Hans J ^e  

^a HILLERØD HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Biomarkers; CEA; Chemoradiation; Rectal cancer; TIMP 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIATION DOSE; RECTUM CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650234857     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998.
2. Obrand DI and Gordon PH: Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 40: 15-24, 1997.
3. Wolpin BM, Meyerhardt JA, Mamon HJ and Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 57: 168-185, 2007.
4. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW and van de Velde CJ: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Eng J Med 345: 638-646, 2001.
5. Vuong T, Belliveau PJ, Michel RP, Moftah BA, Parent J, Trudel JL, Reinhold C and Souhami L: Conformai preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: Early results of a phase I/II study. Dis Colon Rectum 45: 1486-1493; discussion 1493-1485, 2002.
6. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A and Oates J: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24: 668-674, 2006.
7. Wong RK, Tandan V, De Silva S and Figueredo A: Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev: CD002102, 2007.
8. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr.: ASCO 2006 update of recommendations for the use of tumour markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.
9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C and Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360, 2007.
10. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS and Chang SC: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124: 169-174, 2005.
11. Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F and Geissler M: Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: Role of CEA and CA19-9. Anticancer Res 25: 1787-1793, 2005.
12. Moller Sorensen N, Vejgaard Sorensen I, Ornbjerg Wurtz S, Schrohl AS, Dowell B, Davis G, Jarle Christensen I, Nielsen HJ and Brunner N: Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 43: 774-786, 2008.
13. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N and Stephens RW: Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80: 495-503, 1999.
14. Nielsen HJ, Brunner N, Frederiksen C, Lomholt AF, King D, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S and Christensen IJ: Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection. Scand J Gastroenterol 43: 242-248, 2008.
15. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sorensen S, Overgaard J, Lilja H, Harris A, Murphy G and Brunner N: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8: 156-164, 2002.
16. Waas ET, Hendriks T, Lomme RM and Wobbes T: Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48: 700-710, 2005.
17. Hammer JH, Basse L, Svendsen MN, Werther K, Brunner N, Christensen IJ and Nielson HJ: Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer. Colorectal Dis 8: 168-172, 2006.
18. Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N and Glimelius B: TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13: 4117-4122, 2007.
19. Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N and Christensen IJ: Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 42: 1889-1896, 2006.
20. Nielsen HJ, Christensen IJ and Brunner N: A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1. Scand J Gastroenterol 45: 200-207, 2010.
21. Ferenschild FT, Vermaas M, Verhoef C, Dwarkasing RS, Eggermont AM and de Wilt JH: Abdominosacral resection for locally advanced and recurrent rectal cancer. Br J Surg 96: 1341-1347, 2009.
22. Elwanis MA, Maximous DW, Elsayed MI and Mikhail NN: Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: Prospective phase II trial. World J Surg Oncol 7: 52, 2009.
23. Gollins SW, Myint S, Susnerwala S, Haylock B, Wise M, Topham C, Samuel L, Swindell R, Morris J, Mason L and Levine E: Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: A phase I trial (NWCOG-2). Br J Cancer 101: 924-934, 2009.
24. Frederiksen C, Lomholt AF, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N and Nielsen HJ: Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 29: 75-81, 2009.
25. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W and Brunner N: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6: 4292-4299, 2000.
26. Goldstein MJ and Mitchell EP: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23: 338-351, 2005.
27. Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, Yu FJ and Hsieh JS: Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39: 245-250, 2007.
28. Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, Osada S, Ichikawa Y and Shimada H: Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 15: 3433-3439, 2008.
29. Kelley ST, Coppola D, Yeatman T and Marcet J: Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. Clin Colorectal Cancer 5: 114-118, 2005.
30. Aldulaymi B, Christensen IJ, Soletormos G, Jess P, Nielsen SE, Brunner N and Nielsen HJ: Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer. Anticancer Res 30: 233-237, 2010.
31. Hammarstrom S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81, 1999.
32. Pereira TN, Lewindon PJ, Smith JL, Murphy TL, Lincoln DJ, Shepherd RW and Ramm GA: Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol 41: 576-583, 2004.
33. Ulrich D, Noah EM, von Heimburg D and Pallua N: TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 111: 1423-1431, 2003.
34. Lindsay MM, Maxwell P and Dunn FG: TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40: 136-141, 2002.
35. Cai G, Zhang X, Hong Q, Shao F, Shang X, Fu B, Feng Z, Lin H, Wang J, Shi S, Yin Z and Chen X: Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol Dial Transplant 23: 1861-1875, 2008.
36. Allen SD, Padhani AR, Dzik-Jurasz AS and Glynne-Jones R: Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. Am J Roentgenol 188: 442-451, 2007.
37. Kapsoritakis AN, Kapsoritaki AI, Davidi IP, Lotis VD, Manolakis AC, Mylonis PI, Theodoridou AT, Germenis AE and Potamianos SP: Imbalance of tissue inhibitors of metalloproteinases (TIMP) -1 and -4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol 8: 55, 2008.
38. Holten-Andersen MN, Brunner N, Christensen IJ, Jensen V and Nielsen HJ: Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scand J Clin Lab Invest 62: 223-230, 2002.
39. Wiercinska-Drapalo A, Jaroszewicz J and Flisiak R, Prokopowicz D: Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol 9: 2843-2845, 2003.